{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:08:17Z","timestamp":1770667697289,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by the presence of renal cysts. Over time the expanding cysts lead to progressive renal failure. The use of tolvaptan, a V<jats:sub>2<\/jats:sub>-receptor antagonist, was recently approved in ADPKD patients. It was demonstrated that tolvaptan get slower decline in Kidney function compared with placebo. Idiosyncratic hepatic toxicity was described in patients receiving tolvaptan, with elevations in aminotransferases levels. We describe the first case reported in the literature in which hepatic toxicity is caused by the association of amoxicillin\/clavulanic acid and tolvaptan.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 41\u2009years old woman with diagnosis of ADPKD had been in treatment with tolvaptan for 16 weeks when an elevation of liver enzyme levels was detected. She had taken autonomously amoxicillin\/clavulanic acid (in doses of 825\/175\u2009mg twice a day for 7\u2009days) about 5 weeks before.<\/jats:p>\n<jats:p>The timing of the event and the kind of hepatocellular injury could be attributed to the concomitance of medication of tolvaptan and amoxicillin\/clavulanic acid.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We highlight the need to careful monitor hepatic enzyme levels in order to recognize early hepatic side effects in ADPKD patients in treatment with tolvaptan and amoxicillin\/clavulanic acid.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-019-1612-7","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T15:03:36Z","timestamp":1574348616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin\/clavulanic acid: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Angela Maria","family":"Pellegrino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Annicchiarico Petruzzelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"1","key":"1612_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015;88(1):17\u201327.","journal-title":"Kidney Int"},{"issue":"10","key":"1612_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrneph.2011.109","volume":"7","author":"JJ Grantham","year":"2011","unstructured":"Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2011;7(10):556\u201366.","journal-title":"Nat Rev Nephrol"},{"issue":"20","key":"1612_CR3","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, et al. Volume progression in polycystic kidney disease. New Engl J of Med. 2006;354(20):2122\u201330.","journal-title":"New Engl J of Med"},{"issue":"3","key":"1612_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"Arlene B. Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012. https:\/\/doi.org\/10.2215\/CJN.09500911.","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"3","key":"1612_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","volume":"66","author":"FA Belibi","year":"2004","unstructured":"Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells1. Kidney Int. 2004;66(3):964\u201373.","journal-title":"Kidney Int"},{"issue":"1","key":"1612_CR6","first-page":"102","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang X, Wu Y, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am SocNephrol. 2008;19(1):102\u20138.","journal-title":"J Am SocNephrol"},{"issue":"10","key":"1612_CR7","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH 2nd1 Gattone","year":"2003","unstructured":"Gattone VH 2nd1, Wang X, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9(10):1323\u20136.","journal-title":"Nat Med"},{"issue":"8","key":"1612_CR8","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","volume":"26","author":"E Meijer","year":"2011","unstructured":"Meijer E, Gansevoort RT, et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant. 2011;26(8):2445\u201353.","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"1612_CR9","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. TEMPO 3:4 trial investigators. N Engl J Med 20. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med 20"},{"key":"1612_CR10","unstructured":"Assessment report Jinarc International non-proprietary name: tolvaptan. Eur Med Agency. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002788\/WC500187923.pdf. Accessed 10 Nov 2015."},{"issue":"3","key":"1612_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Mustafa A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Trasplant. 2016;31(3):337\u201348.","journal-title":"Nephrol Dial Trasplant"},{"issue":"11","key":"1612_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB1 Watkins","year":"2015","unstructured":"Watkins PB1, Lewis JH2, et al. Clinical pattern of Tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38(11):1103\u201313.","journal-title":"Drug Saf"},{"issue":"4","key":"1612_CR13","first-page":"139","volume":"6","author":"U Gresser","year":"2001","unstructured":"Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects -- review of the literature. Eur J Med Res. 2001;6(4):139\u201349.","journal-title":"Eur J Med Res"},{"key":"1612_CR14","first-page":"27","volume":"1655","author":"PB Watkins","year":"2017","unstructured":"Watkins PB. Amoxicillin\/clavulanic acid\/tolvaptan. Reactions. 2017;1655:27\u201310.","journal-title":"Reactions"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1612-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1612-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1612-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T02:01:13Z","timestamp":1605837673000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1612-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1612-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"19 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent for publication was obtained from the patient. A copy of the written consent is available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"426"}}